Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Clinical trial NCT06303193 · RECRUITING
Trial details
- NCT number
- NCT06303193
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-26
- Primary completion
- 2030-01-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.